Biological and clinical implications of the MTHFR C677T polymorphism

Trends in Pharmacological Sciences

Volumn 22, Issue 4, 2001, Pages 195-201

  Ueland, Per Magne ^a   Hustad, Steinar ^a   Schneede, Jorn ^a   Refsum, Helga ^a   Vollset, Stein Emil ^a  

^a UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); FOLIC ACID; FOLIC ACID ANTAGONIST; HOMOCYSTEINE;

ARTICLE; CARDIOVASCULAR DISEASE; COLORECTAL TUMOR; CORRELATION FUNCTION; DNA SYNTHESIS; ENZYME ACTIVITY; ENZYME POLYMORPHISM; FOLIC ACID BLOOD LEVEL; GENOTYPE; HUMAN; LONGEVITY; NEURAL TUBE DEFECT; PRIORITY JOURNAL;

EID: 0035313224     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(00)01675-8     Document Type: Review

References (59)

1. Polymorphisms of methylenetetrahydrofolate reductase and other enzymes: Metabolic significance, risks and impact on folate requirement
2. Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease
3. Homocysteine and cardiovascular disease
4. Neural tube and craniofacial defects with special emphasis on folate pathway genes
5. Folic acid and homocyst(e)ine metabolic defects and the risk of placental abruption, pre-eclampsia and spontaneous pregnancy loss: A systematic review
6. Riboflavin as a determinant of plasma total homocysteine: Effect modification by the methylenetetrahydrofolate reductase C677T polymorphism
7. Identification of a candidate genetic risk factor for vascular disease: A common mutation at the methylenetetrahydrofolate reductase locus
8. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: The result of a meta-analysis
9. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: A HuGE review
10. The controversy over homocysteine and cardiovascular risk
11. -1). The Hordaland homocysteine study
12. The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes
13. Methylenetetrahydrofolate reductase polymorphism affects the change in homocysteine and folate concentrations resulting from low dose folic acid supplementation in women with unexplained recurrent miscarriages
14. Whole-blood folate values in subjects with different methylenetetrahydrofolate reductase genotypes: Differences between the radioassay and microbiological assays
15. A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells
16. The structure and properties of methylenetetrahydrofolate reductase from Escherichia coli suggest how folate ameliorates human hyperhomocysteinemia
17. The role of vitamin B12 in fasting hyperhomocysteinemia and its interaction with the homozygous C677T mutation of the methylenetetrahydrofolate reductase (MTHFR) gene. A case-control study of patients with early-onset thrombotic events
18. Determinants of plasma homocysteine
19. Genomic DNA hypomethylation, a characteristic of most cancers, is present in peripheral leukocytes of individuals who are homozygous for the C677T polymorphism in the methylenetetrahydrofolate reductase gene
20. Folate and carcinogenesis: Evidence, mechanisms and implications
21. Homocysteine and cardiovascular disease: Cause or effect?
22. Opposite effects of plasma homocysteine and the methylenetetrahydrofolate reductase C677T mutation on carotid artery geometry in asymptomatic adults
23. Hyperhomocysteinemia in chronic renal disease
24. Molecular biology of 5,10-methylenetetrahydrofolate reductase
25. The C677T methylenetetrahydrofolate reductase gene mutation in hemodialysis patients
26. Hyperhomocysteinemia in hemodialysis patients: Effects of 12-month supplementation with hydrosoluble vitamins
27. Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: Results of the Vienna multicenter study
28. The association between two common mutations C677T and A1298C in human methylenetetrahydrofolate reductase gene and the risk for diabetic nephropathy in type II diabetic patients
29. The 'thermolabile' variant of methylenetetrahydrofolate reductase and neural tube defects: An evaluation of genetic risk and the relative importance of the genotypes of the embryo and the mother
30. Genetic polymorphisms in methylenetetrahydrofolate reductase and methionine synthase, folate levels in red blood cells, and risk of neural tube defects
31. Maternal vitamin use, genetic variation of infant methylenetetrahydrofolate reductase, and risk for spina bifida
32. Abnormal folate metabolism and mutation in the methylenetetrahydrofolate reductase gene may be maternal risk factors for Down syndrome
33. Polymorphisms in genes involved in folate metabolism as maternal risk factors for Down syndrome
34. A common mutation in the 5,10-methylenetetrahydrofolate reductase gene as a new risk factor for placental vasculopathy
35. Absence of association between a common mutation in the methylenetetrahydrofolate reductase gene and preeclampsia in Japanese women
36. Methylenetetrahydrofolate reductase polymorphisms are not a risk factor for pre-eclampsia/eclampsia in Australian women
37. 677 C→T polymorphism of the methylenetetrahydrofolate reductase gene and preeclampsia
38. MTHFR polymorphism, methyl-replete diets and the risk of colorectal carcinoma and adenoma among US men and women: An example of gene-environment interactions in colorectal tumorigenesis
39. The methylenetetrahydrofolate reductase 677C→T polymorphism and distal colorectal adenoma risk
40. Methylenetetrahydrofolate reductase, diet, and risk of colon cancer
41. Colorectal adenomas and the C677T MTHFR polymorphism: Evidence for gene-environment interaction?
42. Smoking, folate and methylenetetrahydrofolate reductase status as interactive determinants of adenomatous and hyperplastic polyps of colorectum
43. Methylenetetrahydrofolate reductase polymorphisms, folate, and cancer risk: A paradigm of gene-nutrient interactions in carcinogenesis
44. Increased prevalence of methylenetetrahydrofolate reductase C677T variant in patients with inflammatory bowel disease, and its clinical implications
45. Increased prevalence of methylenetetrahydrofolate reductase C677T variant in patients with IBD
46. Inflammatory bowel diseases are not associated with major hereditary conditions predisposing to thrombosis
47. Pathogenicity of thermolabile methylenetetrahydrofolate reductase for vascular dementia
48. Allelic association of the MTHFR gene with schizophrenia
49. Association between the methylenetetrahydrofolate reductase 677C→T missense mutation and schizophrenia
50. The C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene and vascular dementia
51. Analysis of α-1 antichymotrypsin, presenilin-1, angiotensin- converting enzyme, and methylenetetrahydrofolate reductase loci as candidates for dementia
52. Trimethoprim and fasting plasma homocysteine
53. Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis
54. A common mutation in the methylenetetrahydrofolate reductase gene is a determinant of hyperhomocysteinemia in epileptic patients receiving anticonvulsants
55. The C677T mutation in the methylenetetrahydrofolate reductase gene predisposes to hyperhomocysteinemia in children with familial hypercholesterolemia treated with cholestyramine
56. The effect of L-dopa administration and folate deficiency on plasma homocysteine concentrations in rats
57. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD
58. MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil (CMF)
59. A common methylenetetrahydrofolate reductase gene mutation and longevity